Onyia Jude 4

4 · NEUROCRINE BIOSCIENCES INC · Filed Jun 2, 2026

AI-generated summary of this filing

Updated Jun 2, 2026

Neurocrine (NBIX) CSO Onyia Jude Exercises Options, Sells 11,000 Shares

What Happened

Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences (NBIX), exercised 11,000 options and immediately sold 11,000 shares on June 1, 2026.
Exercise: 11,000 shares exercised at a strike of $84.74 per share (total exercise cost ≈ $932,140).
Sale: 11,000 shares sold in the open market at a weighted average price of $160.25 per share (total proceeds ≈ $1,762,710).
This sequence (exercise then same-day sale) is a routine liquidity event rather than an explicit directional bet on the stock.

Key Details

Transaction date: June 1, 2026 (Form filed June 2, 2026 — appears timely).
Codes: M = option exercise/conversion; S = sale.
Sale execution: Broker sold shares under a Rule 10b5-1 trading plan adopted Feb 25, 2026 (Footnote F1). The plan could not be amended after adoption per issuer policy.
Sale price range: shares sold at prices between $160.00 and $160.66 (weighted avg $160.25) (Footnote F2).
Vesting info: the option vests 1/4 on Nov 29, 2022 then 1/48th monthly thereafter (Footnote F3).
Shares owned after the transaction: not disclosed in the provided filing.

Context

This was an exercise of vested options followed by an immediate market sale — effectively converting option value to cash. Because the sale was carried out under a pre-established 10b5-1 plan, it was a pre-planned disposition executed by a broker rather than an ad-hoc open-market sale.

Form 4

Period: 2026-06-01

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
2026-06-01$84.74/sh+11,000$932,140→ 36,846 total
Sale
Common Stock
[F1][F2]
2026-06-01$160.25/sh−11,000$1,762,710→ 25,846 total
Exercise/Conversion
Non-Qualified Stock Option
[F3]
2026-06-01−11,000→ 13,268 total
Exercise: $84.74Exp: 2031-11-29→ Common Stock (11,000 underlying)

Footnotes (3)

[F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
[F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

Signature

/s/ Darin Lippoldt, Attorney-in-Fact|2026-06-02

1 file